Matching articles for "Cidofovir"
Issue 1664 · November 28, 2022
Maribavir (Livtencity) for Cytomegalovirus Infection (online only)

Maribavir ( Livtencity – Takeda), an oral cytomegalovirus (CMV) pUL97 kinase inhibitor, has been approved by the FDA for treatment of post-transplant CMV infection refractory to standard antiviral therapy in…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):e193-4
Maribavir ( Livtencity – Takeda), an oral cytomegalovirus (CMV) pUL97 kinase inhibitor, has been approved by the FDA for treatment of post-transplant CMV infection refractory to standard antiviral therapy in patients ≥12 years old who weigh at least 35 kg.
Issue 1658 · September 5, 2022 Free
Prevention and Treatment of Monkeypox

An outbreak of monkeypox has recently spread around the globe and across the US. Updated information about the current outbreak is available from the CDC.

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):137-9
An outbreak of monkeypox has recently spread around the globe and across the US. Updated information about the current outbreak is available from the CDC.
Issue 1587 · December 16, 2019
Letermovir (Prevymis) for CMV Prophylaxis

The FDA has approved letermovir ( Prevymis – Merck), a cytomegalovirus (CMV) DNA terminase complex inhibitor, for prophylaxis of CMV infection and disease in CMV-seropositive adult recipients of an…

Med Lett Drugs Ther. 2019 Dec 16; 61(1587):199-201
The FDA has approved letermovir ( Prevymis – Merck), a cytomegalovirus (CMV) DNA terminase complex inhibitor, for prophylaxis of CMV infection and disease in CMV-seropositive adult recipients of an allogeneic hematopoietic cell transplant (HCT). Letermovir is the first CMV DNA terminase complex inhibitor to be approved in the US and the only drug specifically indicated for CMV prophylaxis in HCT patients. It is not approved for treatment of CMV infection.
Issue 1556 · September 24, 2018
Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections

The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.

Med Lett Drugs Ther. 2018 Sep 24; 60(1556):153-7
The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.
Issue 127 · March 1, 2013
Antiviral Drugs

The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been…

Treat Guidel Med Lett. 2013 Mar; 11(127):19-30
The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed elsewhere.
Issue 98 · October 1, 2010
Drugs for Non-HIV Viral Infections

The drugs of choice for treatment of non-HIV viral infections and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by…

Treat Guidel Med Lett. 2010 Oct; 8(98):71-82
The drugs of choice for treatment of non-HIV viral infections and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed in another issue of Treatment Guidelines .
Issue 59 · July 1, 2007
Drugs for Non-HIV Viral Infections

The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA.…

Treat Guidel Med Lett. 2007 Jul; 5(59):59-70
The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used in the prevention of viral infections are discussed in the " Adult Immunization " issue of Treatment Guidelines .
Issue 32 · April 1, 2005
Drugs for Non-HIV Viral Infections

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the…

Treat Guidel Med Lett. 2005 Apr; 3(32):23-32
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the FDA.
Issue 1148 · January 20, 2003 Free
Smallpox Vaccination - Clarification

The single sentence on vaccination site care in our recent article on Smallpox Vaccination (Vol. 45, page 2) needs clarification. In the past, the vaccination site was generally left uncovered, but current…

Med Lett Drugs Ther. 2003 Jan 20; 45(1148):8
The single sentence on vaccination site care in our recent article on Smallpox Vaccination (Vol. 45, page 2) needs clarification. In the past, the vaccination site was generally left uncovered, but current plans for Phase I call for it to be covered with both gauze to absorb liquid and a semipermeable membrane such as an Opsite dressing to prevent spread of the virus. This correction has been made in the web version of the issue.
Issue 1147 · January 6, 2003
Smallpox Vaccine

Because of concerns about the possibility of bioterrorism involving smallpox, the US government is reinstituting smallpox vaccination ( https://www.cdc.gov/smallpox/; www.idsociety.org/bt/toc.htm ).…

Med Lett Drugs Ther. 2003 Jan 6; 45(1147):1-3
Because of concerns about the possibility of bioterrorism involving smallpox, the US government is reinstituting smallpox vaccination ( https://www.cdc.gov/smallpox/; www.idsociety.org/bt/toc.htm ). Vaccination is currently expected to proceed in three phases: the military and hospital smallpox response teams first, other health care workers, police and firefighters second, and the general public in the third phase. Except for the military, vaccination will be voluntary.
Issue 1123 · February 4, 2002
Drugs for Non-HIV Viral Infections

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some…

Med Lett Drugs Ther. 2002 Feb 4; 44(1123):9-16
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some new recommendations for old drugs have been added.
Issue 1115 · October 15, 2001
Drugs and Vaccines Against Biological Weapons

Concerns have arisen anew about possible use of biological weapons. The pathogens considered most likely to be used for this purpose are discussed in this article. A good source for additional information is…

Med Lett Drugs Ther. 2001 Oct 15; 43(1115):87-9
Concerns have arisen anew about possible use of biological weapons. The pathogens considered most likely to be used for this purpose are discussed in this article. A good source for additional information is www.usamriid.army.mil/education/bluebook.html .
Issue 1067 · December 3, 1999
Drugs for Non-HIV Viral Infections

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's] table.

Med Lett Drugs Ther. 1999 Dec 3; 41(1067):113-20
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's] table.
Issue 1046 · February 12, 1999
Drugs and Vaccines Against Biological Weapons

Concerns persist about the possible use of biological weapons. Among the many organisms found in nature that cause serious infections, only a few have the combination of pathogenicity, stability and ease of…

Med Lett Drugs Ther. 1999 Feb 12; 41(1046):15-6
Concerns persist about the possible use of biological weapons. Among the many organisms found in nature that cause serious infections, only a few have the combination of pathogenicity, stability and ease of production needed to make effective biological warefare agents.
Issue 1006 · August 1, 1997
Drugs for Non-HIV Viral Infections

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future issue.

Med Lett Drugs Ther. 1997 Aug 1; 39(1006):69-76
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future issue.
Issue 994 · February 14, 1997
More New Drugs for HIV and Associated Infections

Four new drugs have become available in the USA for HIV infection or its complications. Nevirapine ( Viramune - Roxane), intravenous cidofovir ( Vistide - Gilead), and amphotericin B oral suspension (…

Med Lett Drugs Ther. 1997 Feb 14; 39(994):14-6
Four new drugs have become available in the USA for HIV infection or its complications. Nevirapine ( Viramune - Roxane), intravenous cidofovir ( Vistide - Gilead), and amphotericin B oral suspension ( Fungizone Oral Suspension - Bristol-Myers Squibb) have been approved by the US Food and Drug Administration; nelfinavir ( Viracept - Agouron) is currently available only through an "Expanded Access Program."